Comment: AbbVie, Cerevel Therapeutics could point to fragmented markets, different mechanisms of action for overlapping drugs
AbbVie and Cerevel Therapeutics have overlapping drugs in use or in the pipeline that could draw scrutiny from the US Federal Trade Commission in its review of their $8.7 billion deal....To view the full article, register now.
Already a subscriber? Click here to view full article